Articles tagged with Allergic Reactions
Scientists at Indiana University School of Medicine discovered differences in FOXP3 isoforms controlling Treg cells and their impact on the immune system. These findings may lead to new treatments for autoimmune diseases and allergies.
A new study published in the Journal of Allergy and Clinical Immunology: In Practice found that infants under 12 months who undergo oral immunotherapy have a better safety profile compared to older preschoolers. The treatment, which involves gradually increasing exposure to peanut flour, is highly effective and safe for this age group.
A team of researchers at the University of Texas at Austin has developed a new therapeutic that uses transmembrane stem cell factor to treat ischemia and stroke without causing allergic reactions. The therapeutic, delivered in engineered lipid nanocarriers, shows promise in enhancing revascularization in ischemic tissues.
Researchers at the Messerli Research Institute developed a lozenge that compensates for micronutrient deficiencies in immune cells, reducing inflammation and allergic reactions. The study showed a 45% reduction in symptom burden during peak pollen season, presenting a new approach to allergy care.
A recent study published by the Murdoch Children's Research Institute found no significant association between caesarean birth and the development of food allergies in infants. The research involved over 2,000 infants and suggested that babies born via caesarean delivery are not at a higher risk of developing food allergies.
Patients with a reported penicillin allergy have higher rates of dental implant failure. Alternative antibiotics prescribed during surgery also linked to increased failure rates. The study suggests that testing for actual allergies may improve outcomes.
Researchers have identified formononetin as a potential therapeutic for treating food allergies, which affect nearly 10% of the world population. The plant compound has been shown to decrease IgE production and influence gene and protein targets regulated in food allergy and mast cell diseases.
A Rutgers analysis of Medicare database found that two IV iron formulations have a much higher chance of provoking severe allergic attacks. The risk was highest for iron dextran and ferumoxytol, with rates three to eight times higher than ferric gluconate.
Researchers verified the cause of allergic disorders by identifying plasma B cells secreting E-type immunoglobulin in the thymus of mice models. The study found that thymus-derived E-type immunoglobulin promotes food-induced anaphylactic reactions by increasing mast cell numbers in the intestine.
The Wilderness Medical Society has published evidence-based guidelines for anaphylaxis treatment in remote areas. The guidelines recommend administering intramuscular epinephrine as the primary prehospital treatment, while also discussing prevention strategies such as extracting additional epinephrine from autoinjectors and using expir...
The NIH is conducting a clinical trial to investigate rare but serious systemic allergic reactions to COVID-19 mRNA vaccines. Participants will receive a second dose of vaccine under controlled conditions to determine safe dosing, while breathing tests and blood draws monitor their response. The study aims to provide insights into mech...
Researchers found an association between a specific HLA-DPB1 gene variant and poor response to sublingual immunotherapy (SLIT) for Japanese cedar pollinosis. The study suggests that genotyping the HLA-DPB1 gene could help predict patient responsiveness to SLIT.
Researchers developed a microneedle treatment that increased desensitization rates to peanut allergy in mice, outperforming existing immunotherapy methods. The novel approach achieved significant results using lower doses of allergen, offering new hope for millions suffering from peanut allergy.
A new study found that serious allergic reactions to food among children have flattened since changes to Australian infant feeding guidelines. The research showed a slowing rate of increase in hospital admissions for food anaphylaxis among young children and teenagers, but overall rates remain high. Experts emphasize the need for effec...
A large study found that patients with a history of allergic-like reactions to iodinated contrast media are susceptible to similar reactions from commonly used MRI contrast agents. Premedication or switching to a different MRI contrast agent may reduce risk in patients who have had previous contrast agent reactions.
A systematic review and meta-analysis found that the risk of immediate allergic reactions to a second dose of SARS-CoV-2 mRNA vaccines is low among patients who experienced an immediate allergic reaction to their first dose. The study included 1,366 patients and showed no significant increase in severe immediate reactions or anaphylaxis.
Two new treatments have been found to induce peanut allergy remission in children, with about half achieving remission and experiencing significant improvements in quality of life. The combination treatment and oral immunotherapy alone were both highly effective, providing substantial benefits for children's health and well-being.
Researchers found sublingual immunotherapy with house dust mite extract to be effective in reducing signs and symptoms of atopic dermatitis. The treatment, administered over 18 months, resulted in significant improvements in pruritus and lesions, with rare side effects.
Researchers have created a range of permanent hair dyes that avoid the allergenic properties of traditional formulations, producing a range of hues from rosy pinks to deep blacks. The new dyes were found to be less reactive toward proteins and generated a reduced inflammatory response in cells compared to PPD.
A randomised controlled trial found that most young children treated with peanut immunotherapy achieved desensitisation after two and a half years of treatment, while one in five remained in remission. Younger children under one year old were more likely to achieve remission, suggesting early interventions may provide better outcomes.
A clinical trial found that peanut oral immunotherapy desensitized most highly allergic children and induced remission in one-fifth. Younger children and those with lower levels of peanut-specific antibodies were more likely to achieve remission, with 71% of 1-year-olds experiencing remission.
A study published in Cell Reports reveals that LPS protects against developing asthma when combined with allergens containing cysteine protease enzymatic activity, but promotes development when paired with allergens lacking this enzyme. This protective effect relies on the production of GM-CSF by non-classical monocytes.
A recent study found that over 50% of products containing sesame did not declare it on the label, leading to accidental ingestion and allergic reactions. Clear and specific product labeling is essential for preventing adverse reactions, especially anaphylaxis, in food-allergic individuals.
Researchers found that antihistamines improve responses to immune checkpoint inhibitors in cancer patients, particularly those with pre-existing allergies or high plasma histamine levels. The study suggests targeting the histamine receptor HRH1 may be a useful treatment approach.
Two new studies show that people who think they'll have an allergic reaction or believe they've had one to the first vaccine can still be fully vaccinated. The studies found that 100 patients with PEG allergies and 25 patients with adverse events following immunization tolerated the full vaccine series without severe symptoms.
A new case study presents a medially challenging situation where NSAIDs triggered anaphylactic reactions in a female runner. The patient's symptoms worsened with exercise, emphasizing the importance of being aware of this phenomenon and taking preventive measures.
Researchers found nearly all employees with a history of severe allergic reactions could become fully vaccinated, despite higher reported symptoms. The study suggests COVID-19 vaccines are safe for individuals with high-risk allergy histories.
Cadmium exposure has been linked to an increased risk of developing allergies, particularly asthma, in children. Researchers found that gut bacteria over-produce an enzyme degrading vitamin D after cadmium ingestion, mimicking a deficiency, leading to enhanced allergic reactions.
A study of nearly 53,000 healthcare employees found that individuals with a history of high-risk allergies were more likely to experience allergic reactions after COVID-19 mRNA vaccination. Despite this increased risk, nearly all participants safely received their vaccinations.
Researchers at Uppsala University found that allergic stimulation activates mast cell precursor cells, which can produce cytokine IL-13 contributing to asthma development. This challenges the idea that only mature immune cells are involved in immune reactions.
A Stanford study found that allergic reactions to the new mRNA-based COVID-19 vaccines are rare, typically mild, and treatable. The researchers analyzed 22 potential allergic reactions among healthcare workers who received over 39,000 doses of Pfizer and Moderna vaccines.
A study by Baylor College of Medicine researchers discovered that platelets help mediate an allergic immune response against yeast, clearing it from the lungs. This mechanism involves candidalysin, a peptide toxin that triggers Th2 and Th17 responses, providing essential protection against yeast invasion.
A study assessing Pfizer-BioNTech vaccine safety in highly allergic individuals found a lower incidence of severe adverse reactions compared to previously reported rates. The results suggest the vaccine may be a viable option for these high-risk groups.
A retrospective study of over 3,900 patients found that warming iohexol 350 contrast media did not significantly reduce adverse reactions or extravasations. The results suggest that maintaining the agent at room temperature is non-inferior to warming it to body temperature before injection.
A multi-hospital analysis of patients who experienced allergic reactions to their first mRNA COVID-19 vaccine dose found that all patients who received a second dose tolerated it without complications. The study suggests it's safe for most individuals to receive a second dose, despite initial concerns.
Researchers evaluated the safety of a second Pfizer-BioNTech or Moderna COVID-19 vaccine dose in patients who experienced an allergic reaction to the first dose. The study found no significant increase in adverse events, suggesting the vaccines are safe for those with prior allergic reactions.
Researchers found that cells in specific skin areas develop local memory to contact allergens, leading to faster reactions and a more complex picture of the disease. This discovery may lead to new treatment options for patients with contact allergy.
A research team has identified a naturally abundant venom peptide from ants that can initiate an immune response via a pseudo-allergic receptor MRGPRX2. The study reveals a novel pathway for this receptor, showing P17 induces infiltration of monocytes at the injected site by activating MRGPRX2.
A study by Massachusetts General Hospital found that COVID-19 vaccine skin reactions are rare, affecting approximately 1.9% of recipients after the first dose. The majority of these reactions did not recur after a second dose, providing critical reassurance to individuals with concerns about vaccination.
A comprehensive review of literature on mRNA COVID-19 vaccine cutaneous reactions found that most reactions are harmless and transient, resolving within two to five days. Rare reactions such as herpes zoster reactivation have been reported, but the overall safety profile of the vaccines remains reassuring.
Researchers at Michigan Medicine found that people with venom allergies are nearly 10 times more likely to suffer from mastocytosis, a bone marrow disorder. The study analyzed 27 million US patients and revealed the condition in over 0.1% of venom allergy patients.
The guidelines recommend training staff on food allergies, having epinephrine available, and promoting handwashing to reduce the risk of reactions. Research has found little evidence that food bans work in reducing allergy-related bullying and anxiety.
Researchers at Michigan Medicine are conducting a nationwide trial to investigate allergic reactions to COVID-19 mRNA vaccines. The study aims to identify molecular markers of allergic reactions, with results expected in late summer 2021.
The NIH is conducting a clinical trial to assess the risk of systemic allergic reactions to the Moderna and Pfizer-BioNTech COVID-19 vaccines in people with mast cell disorders or severe allergies. The study aims to identify potential genetic patterns that may predict who is at most risk for these reactions.
Early life antibiotic exposure disrupts beneficial gut bacteria, leading to reduced regulatory T-cells and increased allergic responses. The study found that this disruption occurred as early as six months after birth, persisting into adulthood.
A new study estimates an 'eliciting dose' for peanut allergies, revealing that tiny amounts can trigger reactions in some individuals. The researchers found that exposure to 0.052 milligrams of peanut protein is likely to cause or elicit an allergic reaction in 1% of patients.
The Systems Biology of Early Atopy study aims to integrate biological, environmental, and genetic data to better understand the origins of allergic diseases in children. The 2,500-family study will examine prenatal and early childhood markers of high risk for food allergy and eczema.
A study using real-world data from employees at Mass General Brigham found that the incidence of anaphylaxis was higher than CDC estimates, but still extremely low. The majority of cases recovered without serious complications.
Delayed injection-site reactions can occur in some patients who received the Moderna mRNA-1273 vaccine, researchers say. Most symptoms clear up after a week, and completion of the second dose should not be discouraged.
A study by University of Barcelona researchers reveals a new molecular mechanism controlling anaphylactic reaction severity, identifying the KARS gene mutation as a key player. This discovery holds promise for identifying patients at risk and developing prophylactic measures.
Researchers developed a novel immunotherapy approach using CpG adjuvant to boost immune tolerance to the major cat allergen Fel d 1. The treatment reversed allergy hallmarks and reduced inflammation in allergic mice, offering new hope for treating cat allergy.
A new study published in the Journal of Allergy and Clinical Immunology: In Practice found that exposing children to small, regular doses of peanuts can reduce the risk of severe allergic reactions. Nearly 80% of preschoolers were able to eat a full serving of peanuts without reaction, protecting them from 99% of accidental exposures.
A new soybean line has been developed with reduced allergic sensitivity, which can be tested on pigs to ensure safety for consumers and animals. Eliot Herman's research focuses on eliminating the allergenic protein in soybeans, aiming to improve lives and reduce medical expenditure.
A University of Cincinnati immunologist recommends individuals with contact dermatitis choose facial masks made without elastic to avoid allergic reactions and safely use masks during COVID-19. Cotton-based, knot-tie masks can be a suitable alternative, helping patients manage symptoms and prevent delayed reactions.
The FOURIER analysis showed that Repatha reduced the risk of major coronary events by 18% in patients with prior PCI, who were at a high risk for CV events. This analysis demonstrates the benefit of PCSK9 inhibition with evolocumab in reducing major coronary events.
A breakthrough discovery has revealed a new pathway for the development of allergy treatments by identifying the release of neuropeptide Substance P by sensory neurons upon detection of allergens. This finding suggests that interrupting this pathway could potentially stop allergic immune responses.
Researchers found that maternal antibodies can cross the placenta and trigger allergic reactions in foetal mast cells, leading to lifelong allergies. The study suggests a potential new intervention strategy to limit such transfer and reduce the incidence of neonatal allergies.
A genome-wide association study identified a significant signal from the human leukocyte antigen (HLA) region on chromosome 6, specifically the HLA-B *55:01 allele, associated with a 33% higher relative odds of penicillin allergy. This finding is based on self-reported data and electronic health records of over 1 million individuals.
Researchers found that even cooked carrots can cause allergic reactions in sensitive individuals, as the allergen Dau c 1 retains its structure when heated. This study highlights the importance of acidity and temperature in triggering immune reactions.
A genome-wide association study identified a locus in the HLA-B gene associated with penicillin allergy, with carriers having a 33% higher relative odds. The study also detected a variant in the PTPN22 gene linked to autoimmune diseases and drug-induced liver injury.